Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...

Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases ...

US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form ...

Klotho Neurosciences, Inc., a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, announced that the US Food and Drug Administration (FDA) has ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

A high-level overview of Klotho Neurosciences, Inc. WT EXP 062129 (KLTOW) stock. View (KLTOW) real-time stock price, chart, news, analysis, analyst reviews and more.